|
"許駿"的相關文件
顯示項目 76-100 / 145 (共6頁)
<< < 1 2 3 4 5 6 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2010 |
Treatment Outcomes for Synchronous or Metachronous Hypopharyngeal/ Laryngeal/Oropharyngeal Cancer and Esophageal Cancer
|
許駿; 王駿瑋; 成佳憲; HSU, CHIUN; WANG, CHUN-WEI; CHENG, JASON CHIA-HSIEN |
| 國立臺灣大學 |
2010 |
Induction of DNA Damage-Inducible Gene Gadd45 Beta Contributes to Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Cells
|
歐大諒; 沈盈君; 俞松良; 陳昆鋒; 葉培彥; 林亮音; 許駿; 鄭安理; OU DA-LIANG; SHEN YING-CHUN; YU SUNG-LIANG; CHEN KUEN-FENG; YEH PEI-YEN; LIN LIANG-IN; HSU CHIUN; CHENG ANN-LII |
| 國立臺灣大學 |
2010 |
Design, Translation, and Test of Multi-Dimensional Questionnaires
|
季瑋珠; 許駿; 章殷超; 程劭儀; 高芷華; CHIE, WEI-CHU; HSU, CHIUN; Y.C.CHANG; CHEN, G SHAO-YI; KAO, TZE-WAH |
| 國立臺灣大學 |
2010 |
Potentiating the Anti-Tumor Efficacy of Molecular Targeted Therapy for Hepatocellular Carcinoma by Inhibiting the Insulin-Like Growth Factor Signaling Pathway
|
歐大諒; 許駿; 沈盈君; 鄭安理; OU, DA-LIANG; HSU, CHIUN; SHEN, YING-CHUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
The Aurora Kinase Inhibitor Ve-465 Has Anticancer Effects in Pre-Clinical Studies of Human Hepatocellular Carcinoma
|
許輝吉; 徐志宏; 葉培彥; 黃繼瑩; 郭頌鑫; 許駿; 胡賦強; 鄭永銘; 鄭安理; HSU, HEY-CHI; HSU, CHIH-HUNG; YEH, PEI-YEN; HUANG, CHI-YING; KUO, SUNG-HSIN; HSU, CHIUN; HU, FU-CHANG; JENG, YUNG-MING; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Nuclear Overexpression of Mitotic Regulatory Proteins in Biliary Tract Cancer: Correlation with Clinicopathologic Features and Patient Survival
|
沈盈君; 胡賦強; 鄭永銘; 張毓廷; 林宗哲; 章明珠; 許駿; 鄭安理; SHEN, YING-CHUN; HU, FU-CHANG; JENG, YUNG-MING; CHANG, YU-TING; LIN, ZONG-ZHE; CHANG, MING-CHU; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
INDUCTION OF BIM EXPRESSION CONTRIBUTES TO THE ANTITUMOR SYNERGY BETWEEN SORAFENIB AND MITOGEN-ACTIVATED PROTEIN KINASE/EXTRACELLULAR SIGNAL-REGULATED KINASE KINASE INHIBITOR CI-1040 IN HEPATOCELLULAR CARCINOMA
|
歐大諒; 沈盈君; 梁嘉德; 劉俊陽; 俞松良; 盧彥伸; 許駿 |
| 國立臺灣大學 |
2009 |
Induction of Bim Expression Contributes to the Antitumor Synergy between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular Signal- Regulated Kinase Kinase Inhibitor Ci-1040 in Hepatocellular Carcinoma
|
歐大諒; 沈盈君; 梁嘉德; 劉俊揚; 俞松良; 盧彥伸; 許駿; 鄭安理; OU, DA-LIANG; SHEN, YING-CHUN; LIANG, JA-DER; LIOU, JUN-YANG; YU, SUNG-LIANG; LU, YEN-SHEN; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Overexpressed Focal Adhesion Kinase Predicts a Higher Incidence of Extrahepatic Metastasis and Worse Survival in Hepatocellular Carcinoma
|
詹以吉; 柯博升; 許駿; 王約翰; 劉俊揚; JAN, YEE-JEE; KO, BO-SHENG; HSU, CHIUN; WANG, JOHN; LIOU, JUN-YANG |
| 國立臺灣大學 |
2009 |
A Phase Ii Study of Bevacizumab (B) and Erlotinib (E) in Combination for Asian Patients (Pts) with Advanced/Metastatic Hepatocellular Carcinoma ( Hcc): An Interim Safety Report
|
徐志宏; 邱宗傑; 許駿; 鄭安理; HSU, CHIH-HUNG; CHIOU, TZEON-JYE; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
A Phase Ii Study of Sorafenib in Combination with Tegafur/Uracil (Uft) for Asian Patients with Advanced Hepatocellular Carcinoma (Hcc)
|
沈盈君; 許駿; 徐志宏; 林宗哲; 陳培哲; 邵幼雲; 丁雅慧; 鄭安理; SHEN, YING-CHUN; HSU, CHIUN; HSU, CHIH-HUNG; LIN, ZONG-ZHE; CHEN, PEI-JER; SHAO, YU-YUN; DING, YEA-HUI; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
A Phase Ii Trial of Thalidomide Plus Tegafur/Uracil for Patients with Advanced/Metastatic Hepatocellular Carcinoma (Hcc): Final Report
|
徐志宏; 林宗哲; 沈盈君; 許駿; 鄭安理; HSU, CHIH-HUNG; LIN, ZONG-ZHE; SHEN, YING-CHUN; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Adjuvant Interferon Therapy after Curative Therapy for Hepatocellular Carcinoma (Hcc): A Meta-Analysis
|
許駿; 沈盈君; 陳立宗; 胡賦强; 鄭安理; HSU, CHIUN; SHEN, YING-CHUN; CHEN, LI-TZONG; HU, FU-CHANG; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Evaluation of Vandetanib in Patients with Inoperable Hepatocellular Carcinoma (Hcc): A Randomized, Double-Blind, Parallel Group, Multicentre, Phase Ii Study
|
許駿; 謝瑞坤; 黃偉修; 趙毅; 鄭安理; HSU, CHIUN; HSIEH, RUEY-KUN; HWANG, WEI-SHOU; CHAO, YEE; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Prognostic Factors of Survival in 236 Advanced Hepatocellular Carcinoma Patients Enrolled in Prospective Clinical Trials of Systemic Therapy
|
林宗哲; 邵幼雲; 徐志宏; 許駿; 洪瑞隆; 鄭安理; LIN, ZONG-ZHE; SHAO, YU-YUN; HSU, CHIH-HUNG; HSU, CHIUN; HONG, RUEY-LONG; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Strategies to Prevent Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive Therapy
|
許駿; 魏淑鉁; 鄭安理; 陳培哲; HSU, CHIUN; WEI, SHU-CHEN; CHENG, ANN-LII; CHEN, PEI-JER |
| 國立臺灣大學 |
2009 |
Bortezomib Overcomes Trail Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of P13k/Akt Pathway
|
陳昆鋒; 葉培彥; 許駿; 徐志宏; 盧彥伸; 謝興邦; 陳培哲; 鄭安理; CHEN, KUEN-FENG; YEH, PEI-YEN; HSU, CHIUN; HSU, CHIH-HUNG; LU, YEN-SHEN; HSIEH, HSING-PANG; CHEN, PEI-JER; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Bortezomib Overcomes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway
|
陳昆鋒; 葉培彥; 許駿; 徐志宏; 盧彥伸; 謝興邦; 陳培哲; 鄭安理; CHEN, KUEN-FENG; YEH, PEI-YEN; HSU, CHIUN; HSU, CHIH-HUNG; LU, YEN-SHEN; HSIEH, HSING-PANG; CHEN, PEI-JER; CHENG, ANN-LII |
| 國立臺灣大學 |
2009 |
Phase Ii Study of Cetuximab Plus Weekly Cisplatin and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin for the First-Line Treatment of Advanced Gastric Cancer
|
葉坤輝; 徐志宏; 許駿; 林璟宏; 沈盈君; 邱宗傑; 趙毅; 鄭安理; YEH, KUN-HUEI; HSU, CHIH-HUNG; HSU, CHIUN; LIN, CHING-HUNG; SHEN, YING-CHUN; CHIOU, TZEON-JYE; CHAO, YEE; CHENG, ANN-LII |
| 國立臺灣大學 |
2008-07-31 |
肝癌之轉譯研究:探索分子標靶及治療方法－肝細胞癌之「節拍器式」化學治療藥物及抗血管新生分子靶向治療藥物之最佳化研究(子計畫六)(1/3)
|
許駿 |
| 國立臺灣大學 |
2008-06 |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin, Zhong-Zhe; Hsu, Chiun; Chang, Yeun-Chung; Yu, Chong-Jen; Hsu, Chih-Hung; Lin, Chia-Chi; Cheng, Ann-Lii; Yang, Pan-Chyr; Yang, Chih-Hsin; 林宗哲; 許駿; 張允中; 余忠仁; 徐志宏; 林家齊; 鄭安理; 楊泮池; 楊志新 |
| 國立臺灣大學 |
2008 |
Expression of Mitosis Regulatory Proteins in Biliary Tract Carcinoma: Correlation with Clinico-Pathological Features and Patient Outcome
|
沈盈君; 胡賦強; 鄭永銘; 張玉憲; 林宗哲; 張明志; 許駿; 鄭安理; SHEN, YING-CHUN; HU, FU-CHANG; JENG, YUNG -MING; CHANG, YU-SHIAHN; LIN, ZONG-ZHE; CHANG, MING-CHIH; HSU, CHIUN; CHENG, ANN-LII |
| 國立臺灣大學 |
2008 |
Comparison of Hypoplastic Myelodysplastic Syndrome (Mds) with Normo-/ Hypercellular Mds by International Prognostic Scoring System, Cytogenetic and Genetic Studies
|
黃泰中; 柯博升; 唐季祿; 許駿; 陳建源; 蔡偉; 黃聖懿; 姚明; 陳耀昌; 沈銘鏡; 王秋華; 田蕙芬; HUANG, TAI-CHUNG; KO, BO-SHENG; TANG, JIH-LUH; HSU, CHIUN; CHEN, CHIEN-YUAN; TSAY, WOEI; HUANG, SHANG-YI; YAO, MING; CHEN, YAO-CHANG; SHEN, MING- CHING; WANG, CHIU-HWA; TIEN, HWEI-FANG |
| 國立臺灣大學 |
2008 |
A Revisit of Prophylactic Lamivudine for Chemotherapy-Associated Hepatitis B Reactivation in Non-Hodgkin's Lymphoma: A Randomized Trial
|
許駿; 熊昭; 蘇益仁; 黃偉修; 張明志; 李啟誠; 巫宏博; 田蕙芬; 趙祖怡; 鄭安理; 陳培哲; HSU, CHIUN; HSIUNG, CHAO A.; SU, IH-JEN; HWANG, WEI-SHOU; CHANG, MING-CHIH; LI, CHI-CHENG; WU, HUNG-BO; TIEN, HWEI-FANG; CHAO, TSU-YI; CHENG, ANN -LII; CHEN, PEI-JER |
| 國立臺灣大學 |
2008 |
Expression of the Nuclear Factor Kappa B (Nfkb) P50/P65 Proteins in Hepatocellular Carcinoma (Hcc): Lack of Predictive Value for Response to Thalidomide Treatment
|
許駿; 陳立宗; 趙毅; 沈盈君; 鄭安理; HSU, CHIUN; CHEN, LI-TZONG; CHAO, YEE; SHEN, YING-CHUN; CHENG, ANN-LII |
顯示項目 76-100 / 145 (共6頁)
<< < 1 2 3 4 5 6 > >>
每頁顯示[10|25|50]項目
|
